From the ∗Department of Medical Oncology, Dana-Farber Cancer Institute
†Department of Medicine, Brigham and Women's Hospital
‡Harvard Medical School
§Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
Conflicts of Interest and Source of Funding: E.I.B. has served on advisory boards for Nektar, Novartis, Apexigen, Shionogi, and BMS and received research funding from Lilly, Novartis, Partners therapeutics, Genentech, BMS, and BVD. F.S.H. serves as an advisor or consultant for BMS, Merck, EMD Serono, Novartis, Surface Oncology, Compass Therapeutics, Apricity, Sanofi, Pionyr, Bicara, Checkpoint, Genentech/Roche, Bioentre, Gossamer, Iovance, Trillium, Catalym, Immunocore, Amgen, Kairos, Eisai, Rheos, Zumutor, and Corner Therapeutics.
Authors Contributions: E.I.B. and F.S.H. were involved in writing and reviewing manuscript.
Reprints: Elizabeth I. Buchbinder, MD, 450 Brookline Ave, Boston, MA 02215. E-mail: [email protected].
